Literature DB >> 19406852

Striatal D₂ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study.

E Boot1, J Booij, J R Zinkstok, L de Haan, D H Linszen, F Baas, T A van Amelsvoort.   

Abstract

It has been hypothesised that in subjects with 22q11 deletion syndrome (22q11DS) disturbances of the dopamine (DA) system contribute to their increased risk for cognitive deficits and psychiatric problems. However, central DAergic neurotransmission in 22q11DS has not been investigated. We measured striatal D₂ receptor binding potential (D₂R BP(ND)) using (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide-single photon emission computed tomography ([¹²³I]IBZM SPECT) in 12 adults with 22q11DS and 12 matched controls. Correlations between D₂R BP(ND) and plasma prolactin (pPRL) levels were also determined. 22q11DS subjects and controls had similar D₂R BP( ND). There was a positive correlation between D₂R BP( ND) and pPRL values in controls, but no such relation was found in 22q11DS subjects. This study suggests that a 22q11 deletion does not affect striatal DAergic neurotransmission in the living human brain. However, the disturbed relationship between D₂R BP(ND) and pPRL values suggests DAergic dysfunction at a different level. Further studies on DAergic function in extra-striatal brain regions and under challenged conditions are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406852     DOI: 10.1177/0269881109104854

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

Review 1.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

Review 2.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

Review 3.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

4.  Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.

Authors:  Maria Rogdaki; Céline Devroye; Mariasole Ciampoli; Mattia Veronese; Abhishekh H Ashok; Robert A McCutcheon; Sameer Jauhar; Ilaria Bonoldi; Maria Gudbrandsen; Eileen Daly; Therese van Amelsvoort; Marianne Van Den Bree; Michael J Owen; Federico Turkheimer; Francesco Papaleo; Oliver D Howes
Journal:  Mol Psychiatry       Date:  2021-05-12       Impact factor: 15.992

5.  Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects.

Authors:  Barbara A de Weijer; Elsmarieke van de Giessen; Thérèse A van Amelsvoort; Erik Boot; Breg Braak; Ignace M Janssen; Arnold van de Laar; Eric Fliers; Mireille J Serlie; Jan Booij
Journal:  EJNMMI Res       Date:  2011-12-16       Impact factor: 3.138

6.  Striatal dopamine D2/3 receptor availability in treatment resistant depression.

Authors:  Bart P de Kwaasteniet; Chedwa Pinto; Henricus G Ruhé; Eric H G Ruhé; Guido A van Wingen; Jan Booij; Damiaan Denys
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study.

Authors:  Esther D A van Duin; Jenny Ceccarini; Jan Booij; Zuzana Kasanova; Claudia Vingerhoets; Jytte van Huijstee; Alexander Heinzel; Siamak Mohammadkhani-Shali; Oliver Winz; Felix Mottaghy; Inez Myin-Germeys; Thérèse van Amelsvoort
Journal:  Psychol Med       Date:  2019-04-02       Impact factor: 7.723

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.